Keywords: |
major clinical study; fatigue; diarrhea; drug efficacy; alpha interferon; neurotoxicity; anorexia; leukopenia; nausea; thrombocytopenia; vomiting; myalgia; dose-response relationship, drug; time factors; arthralgia; chill; fever; lymphatic system; confusion; gastrointestinal toxicity; hypotension; psychological aspect; depression; cardiovascular system; recombinant proteins; xerostomia; homosexuality; acquired immune deficiency syndrome; acquired immunodeficiency syndrome; headache; drug dose; kaposi sarcoma; sarcoma, kaposi; drug therapy; dry skin; lethargy; euphoria; adverse drug reaction; mouth; therapy; human immunodeficiency virus 1; opportunistic infections; nervous system; intramuscular drug administration; recombinant; vertigo; interferon type i; intoxication; joint; human; male; priority journal; forgetfulness; recombinant alpha interferon a; blood and hemopoietic system
|